A Real-World Study of β-Thalassemia Major Treatment With Luspatercept in Taiwan

Taiwan β-Thalassemia Major Real-World Study for Luspatercept

This real-world study will assess the efficacy and safety of luspatercept treatment for β-thalassemia major in Taiwan as well as the impact on quality of life.

Inclusion Criteria:

• Participants ≥18 years of age.
• Participants with the diagnosis of transfusion-dependent β-thalassemia major who are eligible to the treatment of luspatercept.
• Before luspatercept treatment, participant's transfusion burden ≥ 24 Red Blood Cell units in 24 weeks, without ≥35-day transfusion free.

Exclusion Criteria:

• Hypersensitivity to the active substance or to any of the excipients.
• Pregnancy.
• Participants requiring treatment to control the growth of extramedullary hematopoiesis (EMH) masses.